Wegovy Approved for Fatty Liver in India, Offering New Hope for Millions

In a significant leap for public health in India, Novo Nordisk popular weight-loss drug, Wegovy, has just received a groundbreaking approval from the Central Drugs Standard Control Organization (CDSCO) to treat Metabolic Dysfunction-Associated Steatohepatitis (MASH), a severe form of fatty liver disease. This makes Wegovy the first and only GLP-1 Receptor Agonist approved globally and in India for this serious condition, which affects an estimated two out of three Indians. The decision, announced on Friday, brings a much-needed new treatment option for a disease that is quietly becoming a major health crisis across the nation. Fatty Liver Disease, now often called Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is a silent epidemic in India, driven by rising rates of obesity, diabetes, and unhealthy lifestyles. MASH specifically involves fat buildup, inflammation, and liver damage, often progressing to severe conditions like Liver Fibrosis and Cirrhosis without noticeable symptoms until it's too late. The CDSCO approval was based on strong results from the ESSENCE clinical trial, where Wegovy, containing the active ingredient Semaglutide, showed that 63% of patients experienced resolution of steatohepatitis and 37% saw a reduction in liver fibrosis. Interestingly, these liver benefits weren't just due to weight loss, pointing to a broader positive effect on liver health. This approval is a game-changer for millions of Indian patients who currently have limited treatment options for MASH. With Emcure Pharmaceuticals serving as the exclusive distribution partner for Semaglutide in India under the brand name Poviztra, and having recently lowered its starting dose price, access could improve significantly. Experts will now be watching closely to see how quickly Wegovy becomes available and integrated into treatment plans, and how it impacts the rising burden of liver disease and related metabolic disorders across the country.